A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS (Barcelona) secures a 1.5 million-euro investment from Invivo Ventures

by Invivo Capital

Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating hematological malignancies. The company raised

Read more

Advances in gene therapy for retinitis pigmentosa due to RPGR gene mutation

by DBGen Ocular Genomics

In the first months of 2020, positive results in gene therapy of X-linked retinitis pigmentosa (XLRP) have been reported. XLRP is an inherited genetic disorder that causes progressive vision loss, mai...

Read more

Researchers identify a fundamental protein to guarantee liver regeneration

by Universitat de Barcelona

Researchers from the Faculty of Medicine of the University of Barcelona and the CELLEX Biomedical Research Centre from IDIBAPS, in collaboration with scientists from the University of Sydney, Universi...

Read more

The Sant Pau Research Institute (IR Sant Pau) and the UAB create the Joint Research Unit in Genomic Medicine UAB – IR Sant Pau

by Hospital de la Santa Creu i Sant Pau

The Research Institute of the Hospital de la Santa Creu i Sant Pau and the Autonomous University of Barcelona have created the Joint Research Unit in Genomic Medicine UAB – IR Sant Pau with the aim ...

Read more

Stargardt’s disease: the research being conducted

by BMF Barcelona Macula Foundation: Research for Vision

There is still no treatment for Stargardt’s disease, which mainly affects young people. However, the research is highly intensive and encouraging

Read more

A gene therapy based clinical trial for Fanconi anemia patients offers its first successful results

by Universitat Autònoma de Barcelona (UAB)

A study, in which Dr. Jordi Surrallés, Professor of Genetics at the UAB, and his research group have participated, presents the first clinical demonstration of engraftment and expansion of gene-corre...

Read more

Luxturna: the first licensed gene therapy for rare inherited eye disorder is recommended by NICE

by Asphalion

A draft NICE guidance recommends Voretigene Neparvovec (also called Luxturna) to treat people with vision loss caused by inherited retinal dystrophy from confirmed RPE65 gene mutations who have enough...

Read more

New gene therapy for autosomal dominant retinitis pigmentosa

by DBGen Ocular Genomics

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form o...

Read more

CIC bioGUNE researchers decode new extremophile viruses whose assembly is related to human viruses

by CIC bioGUNE

The researchers have studied two viruses which live in salt lakes and have an extraordinary survival capacity, and are crucial in understanding some of the viruses of today.

Read more

Asphalion attended CardioReGenix H2020 project kick-off meeting

by Asphalion

The European Union has awarded a grant of 15€ million for a research programme – CardioReGenix – to support new gene therapy approaches for the treatment of heart disease.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...


Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Fertinagro Biotech y Auravant, alianza p...

by Auravant

El grupo Fertinagro se suma a la agricultura 4.0, junto a Auravant, pa...

Photos Stream